Cookie Notice
By continuing to use this website, you consent to our use of cookies and the other terms of our Privacy Policy.
For more information, please visit our Privacy Policy.
If you would like to learn more about BRONCHITOL, have one of our sales representatives contact you, or get updates when they become available, please fill out the fields below.
I’m interested in:
To request specific medical information about BRONCHITOL or to report adverse events or product complaints, please contact the Medical Information Department.
Adverse events may also be reported to the FDA’s MedWatch Program at 1-800-FDA-1088 or www.fda.gov/medwatch.
Mail:
Chiesi USA, Inc.
175 Regency Woods Place
Suite 600
Cary, NC 27518
Phone:
Email:
Fax:
(866) 443-3092
BRONCHITOL is contraindicated in patients with hypersensitivity to mannitol or to any of the capsule components. BRONCHITOL is contraindicated in patients who fail to pass the BRONCHITOL Tolerance Test (BTT).
BRONCHITOL can cause bronchospasm, which can be severe in susceptible patients. Because of the risk of bronchospasm, prior to prescribing BRONCHITOL, patients must pass the BRONCHITOL Tolerance Test (BTT). The BTT must be administered under the supervision of a healthcare practitioner who can treat severe bronchospasm.
Patients who pass the BRONCHITOL tolerance test (BTT) may experience bronchospasm with add-on maintenance therapy with BRONCHITOL. Patients should premedicate with an inhaled short-acting bronchodilator prior to each administration of BRONCHITOL. If bronchospasm occurs, immediately discontinue BRONCHITOL and treat bronchospasm with an inhaled short-acting bronchodilator.
Hemoptysis can occur with BRONCHITOL use. Monitor patients with history of episodes of hemoptysis. If hemoptysis occurs, discontinue use of BRONCHITOL.
Most common adverse reactions (≥3%) include cough, hemoptysis, oropharyngeal pain, vomiting, bacteria sputum identified, pyrexia, and arthralgia.
BRONCHITOL® (mannitol) inhalation powder is a sugar alcohol indicated as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis. Use BRONCHITOL only in adults who have passed the BRONCHITOL Tolerance Test.
Open
Close